Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin

Garg, Pankaj; Morris, Paul D; Fazlanie, Asma Lina; Vijayan, Sethumadhavan; Dancsó, Balázs; Dastidar, Amardeep Ghosh; Plein, Sven; Müeller, Christian; Haaf, Philip

doi:10.1007/s11739-017-1612-1

Cited by 245 publications

(184 citation statements)

References 52 publications

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…Lapatinib hardly altered the echocardiogram variables and NT-proBNP, suggesting that lapatinib may not damage the LV systolic and diastolic function during the acute phase. cTnI has known to act on myocardial contraction by regulating the calcium-dependent interaction of actin and myosin 16,17 . Although the mechanisms by which cTnI is released into the bloodstream are not fully understood, it is a more sensitive blood biochemical markers for cardiac injuries than CK, AST, and LDH 16,17 .…”

Section: Discussionmentioning

confidence: 99%

“…cTnI has known to act on myocardial contraction by regulating the calcium-dependent interaction of actin and myosin 16,17 . Although the mechanisms by which cTnI is released into the bloodstream are not fully understood, it is a more sensitive blood biochemical markers for cardiac injuries than CK, AST, and LDH 16,17 . It has been reported that the elevation of cTnI has been observed with the repeated administration of lapatinib combined with paclitaxel or trastuzumab 18 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Precise safety pharmacology studies of lapatinib for onco-cardiology assessed using in vivo canine models

Ando

Wada

Cao

2020

Sci Rep

View full text Add to dashboard Cite

cancer chemotherapies have improved prognosis in cancer patients, resulting in a large and rapidly increasing number of cancer survivors. "onco-cardiology" or "cardio-oncology" is a new discipline for addressing the unanticipated cardiac side effects of newly developed cancer drugs. Lapatinib, a tyrosine kinase inhibitor suppressing the epidermal growth factor receptor and ErbB2, has been used in advanced or metastatic breast cancer treatment. Reportedly, lapatinib has induced cardiovascular adverse events including Qt-interval prolongation and heart failure. However, they have not been predicted by preclinical studies. Hence, a new method to assess the tyrosine kinase inhibitor-induced adverse effects needs to be established. Here, we intravenously administered lapatinib to halothaneanaesthetised dogs, evaluating cardiohemodynamic, electrophysiological, and echocardiographic profiles for pharmacological safety assessments. We intravenously administered lapatinib to chronic atrioventricular block beagle dogs to assess its proarrhythmic potential. the therapeutic concentration of lapatinib significantly increased total peripheral vascular resistance, QT, QTc, monophasic action potential (MAp) 90(sinus), MAp 90(CL400) , effective refractory period, and plasma concentration of cardiac troponin i (ctni), suggesting that lapatinib prolonged the ventricular repolarization without inducing lethal ventricular arrhythmia. careful monitoring of plasma ctni concentration and an electrocardiogram could be supportive biomarkers, predicting the onset of lapatinib-induced cardiovascular adverse events.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Precise safety pharmacology studies of lapatinib for onco-cardiology assessed using in vivo canine models

Ando

Wada

Cao

2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Cardiac troponin is a specific cardiac structural protein associated with myocyte injury of any type . Although elevated blood Cardiac troponin is not specific to acute coronary events, Cardiac troponin testing is highly sensitive in detecting small amounts of myocardial necrosis .…”

Section: Classification Of MImentioning

confidence: 99%

“…3 Cardiac troponin is a specific cardiac structural protein associated with myocyte injury of any type. 7,8 Although elevated blood Cardiac troponin is not specific to acute coronary events, Cardiac troponin testing is highly sensitive in detecting small amounts of myocardial necrosis. 7 In a study examining the utility of high-sensitivity Cardiac troponin assays, more high-risk patients presenting to the emergency department (ED) with unspecified chest pain were identified and admitted to the hospital than when conventional Cardiac troponin assays were used.…”

Section: Diagnosis Of Nstemimentioning

confidence: 99%

Defining and managing patients with non‐ST‐elevation myocardial infarction: Sorting through type 1 vs other types

Cohen

Visveswaran

2020

Clinical Cardiology

View full text Add to dashboard Cite

Advances in cardiovascular (CV) imaging, redefined electrocardiogram criteria, and high‐sensitivity CV biomarker assays have enabled more differentiated etiological classification of myocardial infarction (MI). Type 1 MI has a different underlying pathophysiology than type 2 through type 5 MI; type 1 MI is characterized primarily by intracoronary atherothrombosis and the other types by a variety of mechanisms, which can occur with or without an atherosclerotic component. In type 2 MI, there is evidence of myocardial oxygen supply‐demand imbalance unrelated to acute coronary atherothrombosis. Types 1 and 2 MI are spontaneous events, while type 4 and type 5 are procedure‐related; type 3 MI is identified only after death. Most type 1 and type 2 MI present as non‐ST‐elevation MI (NSTEMI), although both types can also present as ST‐elevation MI. Because of their different underlying etiologies, type 1 and type 2 NSTEMI have different presentation and prognosis and should be managed differently. In this article, we discuss the epidemiology, prognosis, and management of NSTEMI occurring in the setting of underlying type 1 or type 2 pathophysiology. Most NSTEMI (65%–90%) are type 1 MI. Patients with type 2 MI have multiple comorbidities and causes of in‐hospital mortality among these patients are not always CV‐related. It is important to distinguish between type 1 and type 2 NSTEMI early in the clinical course to allow for the use of the most appropriate treatments that will provide the greatest benefit for these patients.

show abstract

“…Cardiac troponin biomarkers are an essential component used to diagnose acute MI [18]. In the late 1980s, cTnI was proposed as marker of cardiac cell death, and is now widely used and established as the guideline-recommended marker in order to assist in the diagnosis of myocardial injury in clinical pathologies, such as post-surgery myocardium trauma, chemotherapy cardiotoxicity and many other diseases related to cardiac muscle injury [19]. This study aims to measure serum levels of IL-33, CRP and troponin in CAD patients.…”

Section: Introductionmentioning

confidence: 99%

Serum Level of Interleukin-33, C-Reactive Protein, and Troponin in Iraqi Coronary Artery Disease Patients

Al-Obaidi

Al-saffar

2020

eijs

View full text Add to dashboard Cite

Coronary artery disease (CAD) is a condition of an inadequate supply of oxygenated blood to a portion of the myocardium. It typically occurs when there is an imbalance between supply and demand of myocardial oxygen. The most common cause of myocardial ischemia is atherosclerotic disease of an epicardial coronary artery or arteries which is sufficient to cause a regional reduction in myocardial blood flow and inadequate perfusion of the myocardium supplied by the involved coronary artery. Fifty CAD subjects (23 females and 27 males) were enrolled in this study in addition to thirty healthy control subjects (13 female and 17 male). This study aimed to measure the serum levels of interleukin IL-33, C-reactive protein and troponin in CAD and their association with lipid profile by using enzyme-linked immune sorbent assay (ELISA). T results showed that high-density lipoprotein (HDL) was statistically high while differences in cholesterol, triglyceride and lowdensity lipoprotein (LDL) were statistically non-significant between CAD patients and controls. Moreover, the serum level of IL-33 and CRP were statistically higher in patients than controls, while troponin levels were not significantly different. In addition, the present study demonstrates that IL-33, CRP, and Troponin were not associated with lipid profile. The relationship of IL-33 with CRP and troponin was non-significant.

show abstract

Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin

Cited by 245 publications

References 52 publications

Precise safety pharmacology studies of lapatinib for onco-cardiology assessed using in vivo canine models

Precise safety pharmacology studies of lapatinib for onco-cardiology assessed using in vivo canine models

Defining and managing patients with non‐ST‐elevation myocardial infarction: Sorting through type 1 vs other types

Serum Level of Interleukin-33, C-Reactive Protein, and Troponin in Iraqi Coronary Artery Disease Patients

Contact Info

Product

Resources

About